Patents by Inventor Larry M. Gordon
Larry M. Gordon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11951158Abstract: The present disclosure provides compositions and therapies that can address both the symptoms and disorders associated with insufficient surfactant production and hyperoxia. In one embodiment, the composition can be formulated for aerosol delivery during ventilation therapy. The composition can comprise one or more of the following: a PPAR gamma agonist, a surfactant peptide, and one or more phospholipids. The compositions are formulated to provide the complementary benefits of reducing the likelihood of developing or the severity of RDS in infants, as well as protecting and promoting lung maturation in a hyperoxic environment.Type: GrantFiled: November 1, 2021Date of Patent: April 9, 2024Assignee: LINDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTERInventors: Virender K. Rehan, John S. Torday, Frans J. Walther, Alan J. Waring, Larry M. Gordon
-
Publication number: 20230107377Abstract: Peptides suitable for preparation of lung surfactants are described. Examples include one that include a first fragment comprising the amino acid sequence of XWLXRALIKRIQAZI (SEQ ID NO: 1) or a first amino acid sequence having at least 90% sequence identity to SEQ ID NO: 1 and a second fragment comprising the amino acid sequence of RZLPQLVXRLVLRXS (SEQ ID NO: 2) or a second amino acid sequence having at least 90% sequence identity to SEQ ID NO: 2, wherein X is any amino acid but at least one amino acid at the X positions is not cysteine, or Z is any amino acid but at least one amino acid at the Z positions is not methionine. Surfactants that contain such peptides, and related compositions, methods of preparing and using the compositions are also described.Type: ApplicationFiled: June 28, 2022Publication date: April 6, 2023Inventors: Frans J. Walther, Alan J. Waring, Larry M. Gordon
-
COMPOSITIONS AND METHODS FOR ADMINISTERING PPARgamma AGONISTS, SURFACTANT PEPTIDES AND PHOSPHOLIPIDS
Publication number: 20220047681Abstract: The present disclosure provides compositions and therapies that can address both the symptoms and disorders associated with insufficient surfactant production and hyperoxia. In one embodiment, the composition can be formulated for aerosol delivery during ventilation therapy. The composition can comprise one or more of the following: a PPAR gamma agonist, a surfactant peptide, and one or more phospholipids. The compositions are formulated to provide the complementary benefits of reducing the likelihood of developing or the severity of RDS in infants, as well as protecting and promoting lung maturation in a hyperoxic environment.Type: ApplicationFiled: November 1, 2021Publication date: February 17, 2022Inventors: Virender K. Rehan, John S. Torday, Frans J. Walther, Alan J. Waring, Larry M. Gordon -
Compositions and method for administering PPARgamma agonists, surfactant peptides and phosopholipids
Patent number: 11179446Abstract: The present disclosure provides compositions and therapies that can address both the symptoms and disorders associated with insufficient surfactant production and hyperoxia. In one embodiment, the composition can be formulated for aerosol delivery during ventilation therapy. The composition can comprise one or more of the following: a PPAR gamma agonist, a surfactant peptide, and one or more phospholipids. The compositions are formulated to provide the complementary benefits of reducing the likelihood of developing or the severity of RDS in infants, as well as protecting and promoting lung maturation in a hyperoxic environment.Type: GrantFiled: March 6, 2017Date of Patent: November 23, 2021Assignee: LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR—UCLA MEDICAL CENTERInventors: Virender K. Rehan, John S. Torday, Frans J. Walther, Alan J. Waring, Larry M. Gordon -
Publication number: 20210061884Abstract: Peptides suitable for preparation of lung surfactants are described. Examples include one that include a first fragment comprising the amino acid sequence of XWLXRALIKRIQAZI (SEQ ID NO: 1) or a first amino acid sequence having at least 90% sequence identity to SEQ ID NO: 1 and a second fragment comprising the amino acid sequence of RZLPQLVXRLVLRXS (SEQ ID NO: 2) or a second amino acid sequence having at least 90% sequence identity to SEQ ID NO: 2, wherein X is any amino acid but at least one amino acid at the X positions is not cysteine, or Z is any amino acid but at least one amino acid at the Z positions is not methionine. Surfactants that contain such peptides, and related compositions, methods of preparing and using the compositions are also described.Type: ApplicationFiled: June 10, 2020Publication date: March 4, 2021Inventors: Frans J. Walther, Alan J. Waring, Larry M. Gordon
-
COMPOSITIONS AND METHOD FOR ADMINISTERING PPARgamma AGONISTS, SURFACTANT PEPTIDES AND PHOSOPHOLIPIDS
Publication number: 20200289626Abstract: The present disclosure provides compositions and therapies that can address both the symptoms and disorders associated with insufficient surfactant production and hyperoxia. In one embodiment, the composition can be formulated for aerosol delivery during ventilation therapy. The composition can comprise one or more of the following: a PPAR gamma agonist, a surfactant peptide, and one or more phospholipids. The compositions are formulated to provide the complementary benefits of reducing the likelihood of developing or the severity of RDS in infants, as well as protecting and promoting lung maturation in a hyperoxic environment.Type: ApplicationFiled: March 6, 2017Publication date: September 17, 2020Inventors: Virender K. REHAN, John S. TORDAY, Frans J. WALTHER, Alan J. WARING, Larry M. GORDON -
Patent number: 10717777Abstract: Peptides suitable for preparation of lung surfactants are described. Examples include one that include a first fragment comprising the amino acid sequence of XWLXRALIKRIQAZI (SEQ ID NO: 1) or a first amino acid sequence having at least 90% sequence identity to SEQ ID NO: 1 and a second fragment comprising the amino acid sequence of RZLPQLVXRLVLRXS (SEQ ID NO: 2) or a second amino acid sequence having at least 90% sequence identity to SEQ ID NO: 2, wherein X is any amino acid but at least one amino acid at the X positions is not cysteine, or Z is any amino acid but at least one amino acid at the Z positions is not methionine. Surfactants that contain such peptides, and related compositions, methods of preparing and using the compositions are also described.Type: GrantFiled: December 16, 2016Date of Patent: July 21, 2020Assignee: The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical CenterInventors: Frans J. Walther, Alan J. Waring, Larry M. Gordon
-
Patent number: 10358465Abstract: The present invention relates to synthetic lung surfactant compositions that include a novel surface active peptide and a phospholipid, including phospholipase-resistant phospho-glycerol derivatives, phospholipase-resistant phospho-choline derivatives, naturally occurring phospholipids, or a combination thereof. Uses of the surfactant compositions of the present invention to treat endogenous surfactant dysfunctional or deficient lung tissue and to deliver therapeutic agents are also disclosed.Type: GrantFiled: October 20, 2017Date of Patent: July 23, 2019Assignees: Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center, University of RochesterInventors: Alan J. Waring, Frans J. Walther, Larry M. Gordon, Robert H. Notter
-
Publication number: 20190085053Abstract: Peptides suitable for preparation of lung surfactants are described. Examples include one that include a first fragment comprising the amino acid sequence of XWLXRALIKRIQAZI (SEQ ID NO: 1) or a first amino acid sequence having at least 90% sequence identity to SEQ ID NO: 1 and a second fragment comprising the amino acid sequence of RZLPQLVXRLVLRXS (SEQ ID NO: 2) or a second amino acid sequence having at least 90% sequence identity to SEQ ID NO: 2, wherein X is any amino acid but at least one amino acid at the X positions is not cysteine, or Z is any amino acid but at least one amino acid at the Z positions is not methionine. Surfactants that contain such peptides, and related compositions, methods of preparing and using the compositions are also described.Type: ApplicationFiled: December 16, 2016Publication date: March 21, 2019Inventors: Frans J. Walther, Alan J. Waring, Larry M. Gordon
-
Publication number: 20180037610Abstract: The present invention relates to synthetic lung surfactant compositions that include a novel surface active peptide and a phospholipid, including phospholipase-resistant phospho-glycerol derivatives, phospholipase-resistant phospho-choline derivatives, naturally occurring phospholipids, or a combination thereof. Uses of the surfactant compositions of the present invention to treat endogenous surfactant dysfunctional or deficient lung tissue and to deliver therapeutic agents are also disclosed.Type: ApplicationFiled: October 20, 2017Publication date: February 8, 2018Inventors: Alan J. WARING, Frans J. WALTHER, Larry M. GORDON
-
Patent number: 9815869Abstract: The present invention relates to synthetic lung surfactant compositions that include a novel surface active peptide and a phospholipid, including phospholipase-resistant phospho-glycerol derivatives, phospholipase-resistant phospho-choline derivatives, naturally occurring phospholipids, or a combination thereof. Uses of the surfactant compositions of the present invention to treat endogenous surfactant dysfunctional or deficient lung tissue and to deliver therapeutic agents are also disclosed.Type: GrantFiled: February 11, 2013Date of Patent: November 14, 2017Assignees: University of Rochester, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical CenterInventors: Robert H. Notter, Alan J. Waring, Frans J. Walther, Larry M. Gordon, Zhengdong Wang
-
Patent number: 9447127Abstract: The present invention relates to synthetic lung surfactant compositions that contain one or more of phospholipase-resistant phospho-glycerol derivatives, phospholipase-resistant phospho-choline derivatives, and surface active proteins or peptides, more preferably a combination of at least two or all three of these materials. Novel phospholipase-resistant phospho-glycerol derivatives, phospholipase-resistant phospho-choline derivatives, and surface active peptides are also disclosed herein. Uses of the surfactant compositions of the present invention to treat endogenous surfactant dysfunctional or deficient lung tissue, to prepare synthetic peptides for use in the surfactant compositions, and to deliver therapeutic agents are also disclosed.Type: GrantFiled: September 18, 2013Date of Patent: September 20, 2016Assignees: University of Rochester, The Los Angeles Biomedical Research Institute of Harbor-UCLA Medical Center, University of GuelphInventors: Robert H. Notter, Zhengdong Wang, Adrian L. Schwan, Zhongyi Wang, Jason A. Davy, Alan J Waring, Frans Walther, Larry M. Gordon
-
Publication number: 20150125515Abstract: The present invention relates to synthetic lung surfactant compositions that include a novel surface active peptide and a phospholipid, including phospholipase-resistant phospho-glycerol derivatives, phospholipase-resistant phospho-choline derivatives, naturally occurring phospholipids, or a combination thereof. Uses of the surfactant compositions of the present invention to treat endogenous surfactant dysfunctional or deficient lung tissue and to deliver therapeutic agents are also disclosed.Type: ApplicationFiled: February 11, 2013Publication date: May 7, 2015Applicant: UNIVERSITY OF ROCHESTERInventors: Robert H. Notter, Alan J. Waring, Frans J. Walther, Larry M. Gordon, Zhengdong Wang
-
Publication number: 20140044775Abstract: The present invention relates to synthetic lung surfactant compositions that contain one or more of phospholipase-resistant phospho-glycerol derivatives, phospholipase-resistant phospho-choline derivatives, and surface active proteins or peptides, more preferably a combination of at least two or all three of these materials. Novel phospholipase-resistant phospho-glycerol derivatives, phospholipase-resistant phospho-choline derivatives, and surface active peptides are also disclosed herein. Uses of the surfactant compositions of the present invention to treat endogenous surfactant dysfunctional or deficient lung tissue, to prepare synthetic peptides for use in the surfactant compositions, and to deliver therapeutic agents are also disclosed.Type: ApplicationFiled: September 18, 2013Publication date: February 13, 2014Applicants: University of Rochester, The Los Angles Biomedical Research Institute at Harbor-UCLA Medical Center, University of GuelphInventors: Robert H. Notter, Zhengdong Wang, Adrian L. Schwan, Zhongyi Wang, Jason A. Davy, Alan J Waring, Frans Walther, Larry M. Gordon
-
Patent number: 8563683Abstract: The present invention relates to synthetic lung surfactant compositions that contain one or more of phospholipase-resistant phospho-glycerol derivatives, phospholipase-resistant phospho-choline derivatives, and surface active proteins or peptides, more preferably a combination of at least two or all three of these materials. Novel phospholipase-resistant phospho-glycerol derivatives, phospholipase-resistant phospho-choline derivatives, and surface active peptides are also disclosed herein. Uses of the surfactant compositions of the present invention to treat endogenous surfactant dysfunctional or deficient lung tissue, to prepare synthetic peptides for use in the surfactant compositions, and to deliver therapeutic agents are also disclosed.Type: GrantFiled: July 20, 2007Date of Patent: October 22, 2013Assignees: University of Rochester, The Los Angeles BioMedical Research Institute at Harbor—UCLA Medical Center, University of GuelphInventors: Robert H. Notter, Zhengdong Wang, Adrian L. Schwan, Zhongyi Wang, Jason A. Davy, Alan J. Waring, Frans J. Walther, Larry M. Gordon
-
Publication number: 20100055164Abstract: The present invention relates to synthetic lung surfactant compositions that contain one or more of phospholipase-resistant phospho-glycerol derivatives, phospholipase-resistant phospho-choline derivatives, and surface active proteins or peptides, more preferably a combination of at least two or all three of these materials. Novel phospholipase-resistant phospho-glycerol derivatives, phospholipase-resistant phospho-choline derivatives, and surface active peptides are also disclosed herein. Uses of the surfactant compositions of the present invention to treat endogenous surfactant dysfunctional or deficient lung tissue, to prepare synthetic peptides for use in the surfactant compositions, and to deliver therapeutic agents are also disclosed.Type: ApplicationFiled: July 20, 2007Publication date: March 4, 2010Applicants: UNIVERSITY OF ROCHESTER, UNIVERSITY OF GUELPHInventors: Robert H. Notter, Zhengdong Wang, Adrian L. Schwan, Zhongyi Wang, Jason A. Davy, Alan J. Waring, Frans Walther, Larry M. Gordon
-
Patent number: 7538090Abstract: A composition including a C terminal region having residues corresponding to a peptide identified by PDB ID: 1RG3; an N terminal region having residues corresponding to a peptide identified by PDB ID: 1RG4; and a disulfide linkage between the residues near the C terminal region and the N terminal region. A composition including an exogenous peptide comprising amino acid residues comprising a C terminal region; amino acid residues comprising an N terminal region; a helix-loop-helix conformation between the residues comprising the C terminal region and the residues including the N terminal region; and at least one disulfide linkage between the residues comprising the C terminal region and the residues including N terminal region, wherein the residues including the C terminal region and the residues comprising the N terminal region have an amphiphatic property, and wherein the peptide has an a biological activity comparable to native surfactant protein SP-B.Type: GrantFiled: May 19, 2005Date of Patent: May 26, 2009Assignee: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical CenterInventors: Alan J. Waring, Frans J. Walther, Larry M. Gordon, Joseph A. Zasadzinski
-
Publication number: 20040132967Abstract: A therapeutic pharmaceutical composition for the treatment of respiratory disease is disclosed, including particularly Respiratory Distress Syndrome (RDS). The composition is comprised of a synthetic dimer of an N-terminal fragment of Surfactant Protein B (SP-B) that advantageously mimics the functional activity of native human Surfactant Protein B, and to therapeutic methods of administration of such pharmaceutical compositions.Type: ApplicationFiled: December 8, 2003Publication date: July 8, 2004Inventors: Frans J. Walther, Alan J. Waring, Larry M. Gordon, Joseph A. Zasadzinski
-
Patent number: 6660833Abstract: A therapeutic pharmaceutical composition for the treatment of respiratory disease is disclosed, including particularly Respiratory Distress Syndrome (RDS). The composition is comprised of a synthetic dimer of an N-terminal fragment of Surfactant Protein B (SP-B) that advantageously mimics the functional activity of native human Surfactant Protein B, and to therapeutic methods of administration of such pharmaceutical compositions.Type: GrantFiled: February 29, 2000Date of Patent: December 9, 2003Assignee: Harbor-UCLA Research and Education InstituteInventors: Frans J. Walther, Alan J. Waring, Larry M. Gordon, Joseph A. Zasadzinski